Abstract
Dofetilide is a new class III antiarrhythmic drug that selectively prolongs refractoriness without any effect on conduction by blocking potassium outward channels. It has no negative inotropic effect.1–3 We performed a study to determine the clinical safety and efficacy of increasing dosages of intravenous dofetilide for the termination of atrial fibrillation (AF) and atrial flutter (AFl). In addition pharmacokinetic data were collected to investigate a possible relation between dose, plasma concentration, and clinical effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
